Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...
Here to help break down this new painkiller is Dr. Sean Mackey. He’s a Professor of Anesthesiology and Medicine at Stanford ...
The Food and Drug Administration approved Vertex Pharmaceuticals’ “Journavx” on Thursday, greenlighting the non-opioid painkiller for treating moderate to severe pain in what the FDA considered the ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...
The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...
Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...
The Food and Drug Administration late Thursday approved a new non-opioid pain pill from Vertex Pharmaceuticals, one of the most closely-watched drugs in all of biotech. Now comes the real test ...
The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...
The US FDA has approved Journavx, a new pain reliever without the risks for addiction or overdose linked to drugs like Vicodin and OxyContin.
Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November, despite some highly positive news. The U.S. Food and Drug Administration (FDA) approved ...
Vertex Pharmaceuticals (NASDAQ ... the company can now add to its list of approved drugs. On Jan. 30, the FDA granted approval for Vertex's pain medication, Journavx. It's a non-opioid treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results